{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Upadacitinib+15+MG", "query": { "intervention": "Upadacitinib 15 MG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Upadacitinib+15+MG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T12:20:09.757Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02819635", "title": "A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ulcerative Colitis (UC)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 1302, "start_date": "2016-09-26", "completion_date": "2021-12-13", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 149, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 114 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02819635" }, { "nct_id": "NCT03607422", "title": "A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo for Upadacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 912, "start_date": "2018-07-27", "completion_date": "2025-11-11", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03607422" }, { "nct_id": "NCT02706873", "title": "A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo to Upadacitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo to Methotrexate", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1002, "start_date": "2016-02-23", "completion_date": "2022-11-10", "has_results": true, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 32, "location_summary": "La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706873" }, { "nct_id": "NCT03569293", "title": "Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo for Upadacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 912, "start_date": "2018-08-13", "completion_date": "2025-10-10", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 58, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03569293" }, { "nct_id": "NCT07670156", "title": "Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "JAK1 GOF", "STAT1 GOF", "STAT3 GOF", "STAT5B GOF", "STAT6 GOF" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lisa Satter", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2026-10", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 3, "location_summary": "St Louis, Missouri • New York, New York • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07670156" }, { "nct_id": "NCT03682705", "title": "A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "Elsubrutinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for elsubrutinib", "type": "DRUG" }, { "name": "Placebo for upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2018-10-08", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-05-03", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 78, "location_summary": "Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682705" }, { "nct_id": "NCT06016517", "title": "Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-09-01", "completion_date": "2028-12-15", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06016517" }, { "nct_id": "NCT03086343", "title": "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2017-05-09", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 44, "location_summary": "Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086343" }, { "nct_id": "NCT07018206", "title": "Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Axial Spondylarthritis (axSpA)" ], "interventions": [ { "name": "Upadacitinib 15 MG [Rinvoq]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CARE ARTHRITIS LTD.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2026-05", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07018206" }, { "nct_id": "NCT03568318", "title": "A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Topical corticosteroids (TCS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 1533, "start_date": "2018-08-09", "completion_date": "2030-10-23", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-24T12:20:09.757Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03568318" } ] }